Search Results | Showing 1 - 10 of 10 results for "Novartis" |
| | ... to match global standards. Examples of global firms partnering with Chinese businesses include AstraZeneca, Pfizer and Novartis, while Chinese firms such as BeiGene and Legend Biotech have also found multinational partners. "Authorities have been pushing ... |
| | | ... head of global equities Pieter Fourie and his team of six. Some of the stocks in its holdings are: Johnson & Johnson, Novartis, Mondelez, Samsung and Sanofi. Investment screening is conducted in line with Shariah principles overseen by a panel of scholars ... |
| | | ... a US-Australian company developing new treatments for chronic pain which was acquired by Swiss pharmaceutical company Novartis International for US$200 million upfront and US$500 million in additional milestone payments. It is also invested in a number ... |
| | | ... decisions." Roche and Michelin (with D&I scores of 82.5% and 81.5% respectively) are followed by healthcare multinational Novartis, Johnson & Johnson, Astellas Pharma, Contact Energy, Eli Lilly, Colgate-Palmolive and Cisco Systems. |
| | | ... vaccine maker CSL's shares rose 73 cents, or 0.96 per cent, to $76.39 after it announced it'd buy fellow Australian company Novartis' global influenza vaccine business for $US275 million ($A297.54 million). |
| | | ... 7.66 (0.41 per cent) at 1,879.55, while the Nasdaq put on 39.91 (0.97 per cent) to 4,161.46. A series of deals between Novartis, GlaxoSmithKline and Eli Lilly shuffled more than $US20 billion ($A21.51 billion) in assets. The market was also cheered by ... |
| | | ... Beijing implements restrictive policy. But back to the US. JP Morgan, energy company Nexen and healthcare products company Novartis all reported second quarter earnings last night. All beat market expectations. I've said this before. How do you reconcile ... |
| | | ... JP Morgan - like Goldman before it - beat expectations. So have Marriott International, Biogen, Cypress Semiconductor, Novartis, etc. The latest Bloomberg update shows that "earnings have topped estimates by an average of 24 per cent for the 28 companies ... |
| | | ... worth more than $US15 billion and a decline in oil prices boosted investors' confidence in the economy. Swiss drug maker Novartis will acquire all the remaining public shares of US vaccine maker Chiron for a total of $US5.1 billion. While Barrick Gold ... |
|